Spire Healthcare jumps after revealing talks with private equity firms

Spire Healthcare shares jumped 16% to 206p after the FTSE 250 private-hospital operator said it is in preliminary talks with private equity firms Bridgepoint and Triton following a strategic review launched in September. Talks carry no certainty of an offer, but under UK takeover rules the bidders must declare intentions by 5pm on 21 February 2026; Spire has been exploring a sale and ways to unlock value from its £1.4bn property estate. Analysts have previously suggested a full-sale valuation of 325p–450p per share, and trade buyers such as Mediclinic, Circle, Ramsay and Nuffield have been mooted, keeping bids and deal dynamics subject to continued speculation.

Analysis

Market structure: Spire shareholders are the near-term winners (16% intraday move) and private-equity buyers (Bridgepoint, Triton) are potential winners if they can extract property value; competitors (Mediclinic/Ramsay/Circle) face increased consolidation pressure that could raise pricing power in regional hospital markets. A successful trade sale or PE take-private would likely re-rate Spire toward analysts’ 325–450p range, compressing UK healthcare equity discounts and tightening credit spreads on similarly rated hospital issuers; FX impact is modest but sterling could strengthen on a large LSE deal and cross-border M&A flows.

Risk assessment: Tail risks include a blocked sale on CMA/regulatory grounds, PE financing withdrawal at higher rates, or earnings hit from property disposals (low-probability but value-crushing); rising global rates could make leveraged bids unfinanceable within 3–6 months. Immediate window: elevated volatility into the Takeover Panel deadline (5pm 21 Feb 2026); short-term (weeks–months): auction dynamics and potential competing bids; long-term (quarters–years): corporate structure changes (asset strip, REIT sale) altering cashflow and leverage profiles. Hidden dependencies include NHS/private-payer contract mix and lease covenants on the £1.4bn estate; catalysts are declarations by bidders, firm offers, and debt-markets’ appetite for leveraged buyouts.

Trade implications: Direct long in SPI.L is the highest-conviction play given implied upside to 325–450p; hedge market beta with FTSE 250 futures to isolate deal exposure. Options are useful to cap downside — a call-spread into Mar–Jun 2026 offers asymmetric upside if a deal appears by or soon after Feb 21; size positions to 2–3% of portfolio equity exposure total, smaller for options (0.5–1%). Sector rotation: overweight UK private healthcare and M&A-sensitive mid-caps, underweight long-duration healthcare build-to-rent or property REITs that would compete for capital.

Contrarian angles: Consensus assumes either a sale or high bid — missing are financing risk and regulatory friction; the 16% rally is likely underdone versus analyst target mid-point (≈350p), but deal failure risk is nontrivial. Historical peer takeovers in UK healthcare show 35–80% premiums but also post-deal operational disruption; unintended consequence: PE-led property monetization could reduce reported EBITDA and trigger covenant stress, so plan exits around deal milestones, not merely headlines.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Spire Healthcare (SPI.L) at market up to 220p; take 50% off at 325p and the remainder at 450p, with a hard stop-loss at 180p. Time horizon: 3–9 months; increase size by +50% if a firm offer or declaration ≥325p is announced by 21 Feb 2026.
• If liquid, deploy 0.5% portfolio into SPI.L Mar/Jun 2026 300p–400p call spread (buy 300p, sell 400p) to capture asymmetric upside into post-deadline auction window; if options illiquid, use outright equity sized to 0.5% instead.
• Implement a hedged pair: go long SPI.L = 2% portfolio weight and short FTSE 250 futures sized to neutralize market beta (~1% notional equivalent) to isolate M&A idiosyncratic exposure. Close hedge if a firm bid is announced or if SPI.L falls below 180p on volume.
• Contingency rules: if no bidder declaration by 21 Feb 2026 and SPI.L remains <230p, reduce long exposure by 50% (high probability of deal failure priced in); if a competing auction drives price >375p, trim to lock 75% of cumulative gains.